Category: spinal muscular atrophy

New Three-Year Data for Genentech’s Evrysdi (risdiplam)

Posted on 7 May, 2022 - Uncategorised

Long-term improvements in survival and motor milestones in babies with Type 1 Spinal Muscular Atrophy (SMA) – 91% of infants treated with Evrysdi in the FIREFISH study were still alive at three years – – Infants treated with Evrysdi maintained or continued to improve in measures of motor function, including their ability to sit without…